<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Hyperlipidaemia; Lipid-regulating drugs; Hypercholesterolaemia; Cardiovascular disease: prevention: non-drug treatment; Familial hypercholesterolaemia" /><meta name="IX" content="Hyperlipidaemia; Lipid-regulating drugs; Hypercholesterolaemia; Cardiovascular disease: prevention: non-drug treatment; Familial hypercholesterolaemia" /><title>2.12 Lipid-regulating drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1621-lipid-regulating-drugs.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1621-lipid-regulating-drugs.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP1621-lipid-regulating-drugs.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 12 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP747-cardiovascular-system.htm">2 Cardiovascular system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1617-protein-c-concentrate.htm" title="Previous: PROTEIN C CONCENTRATE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP1623-statins.htm" title="Next: Statins">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1><span>2.12 </span>Lipid-regulating drugs</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p>Preventative measures should be taken in individuals with a high risk of developing cardiovascular disease (primary prevention) and to prevent recurrence of events in those with established cardiovascular disease (secondary prevention).</p> <p>Individuals at high risk include those who already have atherosclerotic disease, those with diabetes mellitus aged over 40 years, and those with familial hypercholesterolaemia. The risk also increases with age; those over 75 years are at particularly high risk, especially if they smoke or have hypertension.</p> <p>Preventative measures are also required for other individuals who may be at high risk of developing atherosclerotic cardiovascular disease; those with a 10-year risk of cardiovascular disease<cite><a href="PHP1621-lipid-regulating-drugs.htm#ID0EBRAA" class="tooltip ID0EBRAA">(1)</a></cite> of 20% or more stand to benefit most from drug treatment. The risk is assessed on the basis of lipid concentration as well as smoking status, blood pressure, gender, and age; other risk factors, such as premature menopause, ethnicity, obesity, triglyceride concentration, chronic kidney disease, impaired glucose tolerance, and a family history of premature cardiovascular disease, should also be taken into account when assessing risk in individual patients.</p> <p id="PHP1622">Patients with hypothyroidism should receive adequate thyroid replacement therapy before assessing the requirement for lipid-regulating treatment because correcting hypothyroidism itself may resolve the lipid abnormality. Untreated hypothyroidism increases the risk of myositis with lipid-regulating drugs.</p> <p>Lowering the concentration of low-density lipoprotein (LDL) cholesterol and raising high-density lipoprotein (HDL) cholesterol slows the progression of atherosclerosis and may even induce regression. All patients at high risk of cardiovascular disease should be advised to make lifestyle modifications that include beneficial changes to diet, exercise, weight management, alcohol consumption, and smoking cessation. Lipid-regulating drug treatment must be combined with advice on diet and lifestyle measures, lowering of raised blood pressure (<a title="section: Hypertension and heart failure" href="PHP1034-hypertension-and-heart-failure.htm">section 2.5</a>), the use of low-dose aspirin (<a title="monograph: ASPIRIN (antiplatelet)" href="PHP1531-aspirin-antiplatelet.htm">section 2.9</a>), and management of diabetes (<a title="section: Drugs used in diabetes" href="PHP4032-drugs-used-in-diabetes.htm">section 6.1</a>).</p> <p>A <strong>statin</strong> reduces the risk of cardiovascular disease events, irrespective of serum cholesterol concentration, and is the drug of first choice for primary and secondary prevention of cardiovascular disease. If statins are contra-indicated or not tolerated, a <strong>fibrate</strong> or a <strong>bile acid sequestrant</strong> may be considered for <em>primary</em> or <em>secondary</em> prevention; <strong>nicotinic acid</strong> is also an option for <em>secondary</em> prevention. Fibrates, bile acid sequestrants, or nicotinic acid should not be used in combination with a statin for <em>primary</em> prevention of cardiovascular disease. In secondary prevention of cardiovascular events, if a total cholesterol concentration of less than 4 mmol/litre <em>or</em> a LDL-cholesterol concentration of less than 2 mmol/litre is not achieved with initial treatment, consider treating patients with a ‘high-intensity’ statin (e.g. simvastatin or atorvastatin)—a ‘high-intensity’ statin is one that produces a greater LDL-cholesterol reduction than simvastatin 40 mg; ‘high-intensity’ statins are associated with an increased risk of muscle toxicity—see <a title="BNF:target-block: Statins muscle effects" href="PHP1623-statins.htm#PHP1631">Muscle Effects</a>. Patients with an acute coronary syndrome should also receive treatment with a ‘high-intensity’ statin where appropriate.</p> <p>A statin is also the drug of first choice for treating hypercholesterolaemia and moderate hypertriglyceridaemia. Severe hyperlipidaemia not adequately controlled with a maximal dose of a statin may require the use of an additional lipid-regulating drug such as <strong>ezetimibe</strong> or <strong>colestyramine</strong>; such treatment should generally be supervised by a specialist.</p> <p>A number of conditions, some familial, are characterised by very high LDL-cholesterol concentration, high triglyceride concentration, or both. <strong>Fenofibrate</strong> may be added to statin therapy if triglycerides remain high even after the LDL-cholesterol concentration has been reduced adequately; <strong>nicotinic acid</strong> may also be used to further lower triglyceride or LDL-cholesterol concentration.</p> <p>Combination of a statin with a fibrate or with nicotinic acid carries an increased risk of side-effects (including rhabdomyolysis—see <a title="BNF:target-block: Statins muscle effects" href="PHP1623-statins.htm#PHP1631">Muscle Effects</a>) and should be used under specialist supervision; monitoring of liver function and creatine kinase should also be considered. The concomitant administration of gemfibrozil with a statin increases the risk of rhabdomyolysis considerably—this combination should <strong>not</strong> be used.</p> <p>A statin is recommended for all patients with familial hypercholesterolaemia. A ‘high-intensity’ statin (e.g. rosuvastatin (initiated by a specialist), simvastatin, or atorvastatin) should be considered in order to achieve the recommended reduction in LDL-cholesterol concentration of greater than 50% from baseline; a ‘high-intensity’ statin is one that produces a greater LDL-cholesterol reduction than simvastatin 40 mg—‘high-intensity’ statins are associated with an increased risk of muscle toxicity—see <a title="BNF:target-block: Statins muscle effects" href="PHP1623-statins.htm#PHP1631">Muscle Effects</a>. Patients with heterozygous familial hypercholesterolaemia who have contra-indications to, or are intolerant of, statins should receive ezetimibe. The combination of a statin and ezetimibe can be considered if a statin alone fails to provide adequate control (or if intolerance limits dose titration), and when a switch to an alternative statin is being considered. Patients for whom statins and ezetimibe are inappropriate, should be referred to a specialist for the consideration of treatment with a bile acid sequestrant, nicotinic acid, or a fibrate.</p> <p>The prescribing of drug therapy in homozygous familial hypercholesterolaemia should be undertaken in a specialist centre.</p> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP1623-statins"><a href="PHP1623-statins.htm" title="Statins">Statins</a></li><li id="_PHP1654-bile-acid-sequestrants"><a href="PHP1654-bile-acid-sequestrants.htm" title="Bile acid sequestrants">Bile acid sequestrants</a></li><li id="_PHP1667-ezetimibe"><a href="PHP1667-ezetimibe.htm" title="Ezetimibe">Ezetimibe</a></li><li id="_PHP1671-fibrates"><a href="PHP1671-fibrates.htm" title="Fibrates">Fibrates</a></li><li id="_PHP1693-nicotinic-acid-group"><a href="PHP1693-nicotinic-acid-group.htm" title="Nicotinic acid group">Nicotinic acid group</a></li><li id="_PHP1703-omega-3-fatty-acid-compounds"><a href="PHP1703-omega-3-fatty-acid-compounds.htm" title="Omega-3 fatty acid compounds">Omega-3 fatty acid compounds</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1617-protein-c-concentrate.htm">Previous: PROTEIN C CONCENTRATE </a> | <a class="top" href="PHP1621-lipid-regulating-drugs.htm#">Top</a> | <a accesskey="]" href="PHP1623-statins.htm">Next: Statins</a> ►</div><ol class="cC"><li class="footnote" id="ID0EBRAA"><p>Cardiovascular disease risk may be determined from the <a title="BNF:topic: How to use the Cardiovascular Risk Prediction Charts for Primary Prevention" href="PHP10418-how-to-use-the-cardiovascular-risk-prediction-charts-for-primary-prevention.htm">chart</a> issued by the Joint British Societies (<em>Heart</em> 2005; <strong>91</strong> (Suppl V): v1–v52). The Joint British Societies' ‘Cardiac Risk Assessor’ computer programme may also be used to determine cardiovascular disease risk.</p></li></ol></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>